These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1961 related articles for article (PubMed ID: 32991844)
21. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135 [TBL] [Abstract][Full Text] [Related]
22. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Premkumar L; Segovia-Chumbez B; Jadi R; Martinez DR; Raut R; Markmann A; Cornaby C; Bartelt L; Weiss S; Park Y; Edwards CE; Weimer E; Scherer EM; Rouphael N; Edupuganti S; Weiskopf D; Tse LV; Hou YJ; Margolis D; Sette A; Collins MH; Schmitz J; Baric RS; de Silva AM Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32527802 [TBL] [Abstract][Full Text] [Related]
23. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. Qiao B; Olvera de la Cruz M ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067 [TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847 [TBL] [Abstract][Full Text] [Related]
26. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
28. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2. Konwarh R Front Immunol; 2020; 11():1531. PubMed ID: 32655584 [No Abstract] [Full Text] [Related]
29. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512 [TBL] [Abstract][Full Text] [Related]
30. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Li Y; Lai DY; Zhang HN; Jiang HW; Tian X; Ma ML; Qi H; Meng QF; Guo SJ; Wu Y; Wang W; Yang X; Shi DW; Dai JB; Ying T; Zhou J; Tao SC Cell Mol Immunol; 2020 Oct; 17(10):1095-1097. PubMed ID: 32895485 [No Abstract] [Full Text] [Related]
31. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Papageorgiou AC; Mohsin I Cells; 2020 Oct; 9(11):. PubMed ID: 33105869 [TBL] [Abstract][Full Text] [Related]
32. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Zhou D; Duyvesteyn HME; Chen CP; Huang CG; Chen TH; Shih SR; Lin YC; Cheng CY; Cheng SH; Huang YC; Lin TY; Ma C; Huo J; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Donat RF; Godwin K; Buttigieg KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll MW; Gilbert-Jaramillo J; Knight ML; James W; Owens RJ; Naismith JH; Townsend AR; Fry EE; Zhao Y; Ren J; Stuart DI; Huang KA Nat Struct Mol Biol; 2020 Oct; 27(10):950-958. PubMed ID: 32737466 [TBL] [Abstract][Full Text] [Related]
33. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327 [TBL] [Abstract][Full Text] [Related]
34. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Grant OC; Montgomery D; Ito K; Woods RJ Sci Rep; 2020 Sep; 10(1):14991. PubMed ID: 32929138 [TBL] [Abstract][Full Text] [Related]
35. A human monoclonal antibody blocking SARS-CoV-2 infection. Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817 [TBL] [Abstract][Full Text] [Related]